This $581,052 federal Project Grant award from the National Institute of Child Health and Human Development (CFDA 93.865 - Child Health and Human Development Extramural Research) aims to demonstrate the feasibility of a 3D printed dose-flexible pediatric delivery system for the treatment of toxoplasmosis in children.
The grantee, Texas A&M University System Health Science Center, will develop, assess palatability, and characterize a dose-flexible delivery system containing the drugs pyrimethamine, sulfadiazine, and leucovorin. This system is intended to overcome limitations of current adult dose manipulations and compounding for pediatric use. The project will also evaluate the pharmacokinetics, pharmacodynamics, and palatability of the 3D printed delivery system in animal models and human taste panels. The goal is to advance scientific knowledge on the feasibility and utility of dose-flexible 3D printed delivery systems for pediatric toxoplasmosis treatment, which could potentially benefit other classes of drugs lacking pediatric formulations.